It was in late 2005 that the status of methasterone, in addition to that of four other designer steroids, as an AAS was brought to public awareness by an article published in the Washington Post .  Don Catlin of the UCLA Olympic Laboratory, who conducted the studies, noted methasterone’s similarity to drostanolone. A warning by the FDA was issued soon after to the general public as well as to the distributor, Designer Supplements LLC, for the marketing of this compound.  Methasterone was subsequently added to the World Anti-Doping Agency (WADA) list of prohibited substances in sport.  Despite all of this, methasterone has resurfaced within the supplement industry on several occasions since its banning by WADA. 
(B) (1) Every licensed health professional authorized to prescribe drugs shall keep a record of all controlled substances received and a record of all controlled substances administered, dispensed, or used other than by prescription. Every other person, except a pharmacist or a manufacturer, wholesaler, or other person licensed under section of the Revised Code, who is authorized to purchase and use controlled substances shall keep a record of all controlled substances purchased and used other than by prescription. The records shall be kept in accordance with division (C)(1) of this section.
Drugs can be added and removed from this list by WADA annually, although not all of the banned substances are explicitly named. Caroline Hatton, PhD , a sports anti-doping science consultant, told in a Mar. 12, 2010 email that "A key concept in prohibited lists is that they avoid being finite. Instead of listing all banned drugs one by one, they list entire drug classes and name drugs merely as examples. This is to keep users who took designer drugs from claiming that they didn't break the rules because the drugs they took weren't listed."